Loading stock data…
UFPT
$231.12+4.41 (+1.95%)
After Hours$231.12+0.00 (+0.00%)· Last close Jun 9
UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
UFP Technologies, Inc. in the Healthcare sector is trading at $231.12 with a market capitalization of $1.7B. Wall Street consensus targets $324.50 (2 analysts), implying a +40.4% move over the next 12 months. The stock is currently 16% below its 52-week high of $274.93, remaining 6.4% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +40.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$231.12
Potential Upside
21.7%
Whystock Fair Value$281.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$324.50+40.4%
Range$289.00 – $360.00
Fundamentals
UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.69B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.87
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.64%
Volume
Today's trading volume
234,898
Recent News
Q1 Rundown: UFP Technologies (NASDAQ:UFPT) Vs Other Drug Development Inputs & Services Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including UFP Technologies (NASDAQ:UFPT) and its peers.
UFP Technologies Adds Ryan Stafford As Legal HR Lead In Growth Push
UFP Technologies (NasdaqCM:UFPT) has appointed Ryan Stafford as General Counsel and Senior Vice President of Human Resources. Stafford succeeds longtime executive Chris Litterio, who is retiring from the company. The appointment adds public company legal, HR, and M&A experience to UFP Technologies’ leadership team. For shareholders, this shift comes as UFP Technologies trades around $223.87, with the stock up 29.6% over the past 3 years and 288.1% over the past 5 years. Over the past year,...
3 Russell 2000 Stocks with Warning Signs
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 We Avoid
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
5 Revealing Analyst Questions From UFP Technologies’s Q1 Earnings Call
UFP Technologies delivered results in line with Wall Street’s revenue expectations for Q1 and outperformed on adjusted profitability, driving a positive market reaction. Management attributed the quarter’s growth to strength in medical sales, particularly in robotic surgery, patient surfaces, and interventional segments, which offset declines in nonmedical areas like automotive. CEO Jeff Bailly highlighted the company’s ongoing shift away from nonmedical markets and the ramp-up of four new progr